LDLR and Hypercholesterolemia: The role of PCSK9 in LDLR degradation is further supported by genetic studies showing that gain-of-function mutations in PCSK9 lead to reduced LDLR levels and increased plasma LDL-C, whereas loss-of-function mutations have protective effects against hypercholesterolemia [8].